Brief: Acura Pharmaceuticals, AD Pharma Amend License to LIMITx LTX-03
26/07/2021 21:25
July 26 (Reuters) - Acura Pharmaceuticals Inc ACUR.PK :
* ACURA PHARMACEUTICALS AND AD PHARMA AMEND LICENSE TO
LIMITX™
LTX-03
* ACURA PHARMACEUTICALS INC - AMENDMENT TO EXTEND FDA
ACCEPTANCE
DATE FOR LTX-03 TO FEBRUARY 28, 2022
Source text for Eikon: ID:nGNX3jpSJW
Further company coverage: ACUR.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acura Pharmaceuticals
See all newsBrief: Acura Pharmaceuticals Received A $250,000 Loan From Abuse Deterrent Pharma, LLC on October 11
Brief: Acura Pharmaceuticals Inc Receives $200,000 Loan From Abuse Deterrent Pharma
Brief: Acura Pharmaceuticals Received $250,000 Loan From AD Pharma For Operations Through End Of April 2023
Brief: Acura Pharmaceuticals, AD Pharma Amend License to LIMITx LTX-03
Insight: Novavax bosses cash out for $46 mln with COVID-19 vaccine trials still under way